Chelsea Kotch

Dr. Chelsea Kotch

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 June 2019 in Expert Review of Clinical Immunology
Verified
Journal Article
Closed access
CKChelsea Kotch
Chelsea Kotch
DBDavid Barrett
David Barrett
DTDavid Trent Teachey
David Trent Teachey
Introduction: Cancer-directed immunotherapies are transforming the landscape in oncology as new and exciting therapies move from the laboratory to the bedside. Chimeric antigen receptor T (CAR-T) cells are one of these novel therapies, demonstrating impressive efficacy against B-cell malignancies. With the development of new therapies, it is not uncommon to identify new and unanticipated toxicities. CAR-T cells cause unique toxicities not typically found with traditional cytotoxic chemotherapy or small molecule inhibitors. Areas covered: CAR-T cell associated toxicities include cytokine release syndrome (CRS) and CAR-T cell-related encephalopathy syndrome (CRES), alternatively known as immune effector cell-associated neurotoxicity syndrome (ICANS). Prompt identification and management of CRS and CRES are imperative for the prevention of life-threatening complications of these innovative therapies. This literature review describes the seminal trials of CD19-directed immunotherapy and the pathophysiology and management of the toxicities found with CAR-T cells. In addition, the use of the interleukin-6 receptor antibody tocilizumab for CRS is reviewed. Expert opinion: This review describes the recommended management of CRS and CRES and examines the current limitations in management. Alternative therapies for the treatment of CAR-T cell related toxicities are also explored. Furthermore, the review proposes future directions for research.

9 January 2022 in Neuro-Oncology
Verified
Journal Article
Closed access
PDF file
CKChelsea Kotch
Chelsea Kotch
RARobert Avery
Robert Avery
KGKelly D Getz
Kelly D Getz
EBEric Bouffet
Eric Bouffet
PBPeter de Blank
Peter de Blank
MFMichael J Fisher
Michael J Fisher
Background: Nearly one-third of patients with neurofibromatosis type 1-associated optic pathway glioma (NF1-OPG) fail frontline chemotherapy; however, little is known about risk factors for treatment failure. Methods: We performed a retrospective multi-institutional cohort study to identify baseline risk factors for treatment-refractory/relapsed disease and poor visual outcome in children with NF1-OPG. Refractory/relapsed NF1-OPG was defined as a requirement of two or more treatment regimens due to progression or relapse. Results: Of 111 subjects eligible for inclusion, adequate clinical and visual data were available for 103 subjects from 7 institutions. Median follow-up from the initiation of first chemotherapy regimen was 95 months (range 13-185). Eighty-four (82%) subjects received carboplatin-based frontline chemotherapy. Forty-five subjects (44%) experienced refractory/relapsed disease, with a median time of 21.5 months (range 2-149) from the initiation of first treatment to the start of second treatment. The proportion of patients without refractory/relapsed disease at 2 and 5 years was 78% and 60%. In multivariable analyses, age less than 24 months at initial treatment, posterior tumor location, and familial inheritance were associated with refractory/relapsed NF1-OPG by 2 years. Both age less than 24 months and posterior tumor location were associated with refractory/relapsed NF1-OPG by 5 years. Subjects with moderate to severe vision loss at last follow-up were more likely to have posterior tumor location, optic disc abnormalities, or abnormal visual acuity at initial treatment. Conclusion: Young age, posterior tumor location, and optic disc abnormalities may identify patients with the greatest likelihood of refractory/relapsed NF1-OPG and poor visual outcomes, and who may benefit from newer treatment strategies.

5 May 2024 in Child's Nervous System
Verified
Journal Article
Closed access
PDF file
CKChelsea Kotch
Chelsea Kotch
PBPeter de Blank
Peter de Blank
DGDavid H. Gutmann
David H. Gutmann
MFMichael J. Fisher
Michael J. Fisher

1 November 2019 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
SMSusan Matesanz
Susan Matesanz
CKChelsea Kotch
Chelsea Kotch
CPChristopher Perrone
Christopher Perrone
AWAngela J. Waanders
Angela J. Waanders
BHBrook Hill
Brook Hill
SNSona Narula
Sona Narula

6 February 2023 in Pediatric Neurosurgery
Verified
Journal Article
Open access
PDF file
CKChelsea Kotch
Chelsea Kotch
SBStephanie Nicole Brosius
Stephanie Nicole Brosius
TRThomas De Raedt
Thomas De Raedt
MFMichael Jay Fisher
Michael Jay Fisher
Background: Neurofibromatosis type 1 and neurofibromatosis type 2 are unrelated, distinct genetic disorders characterized by the development of central and peripheral nervous system tumors. Summary: Neurofibromatosis type 1 is the most common inherited tumor predisposition syndrome with a lifelong increased risk of benign and malignant tumor development, such as glioma and nerve sheath tumors. Neurofibromatosis type 2 classically presents with bilateral vestibular schwannoma, yet it is also associated with non-vestibular schwannoma, meningioma, and ependymoma. Historically, the number of effective therapies for neurofibromatosis-related neoplasms has been limited. Key Message: In the past decade, there have been significant advances in the development of precision-based therapies for NF-associated tumors with an increased emphasis on functional outcomes in addition to tumor response. Continued scientific discovery and advancement of targeted therapies for NF-associated neoplasms are necessary to continue to improve outcomes for patients with NF.

26 May 2023 in The Journal of Pediatrics
Verified
Journal Article
Closed access
CKChelsea Kotch
Chelsea Kotch
EDEva Dombi
Eva Dombi
ASAmish C. Shah
Amish C. Shah
KSKatherine Smith
Katherine Smith
SBSymone Brown
Symone Brown
MFMichael J. Fisher
Michael J. Fisher